Results 121 to 130 of about 35,993 (244)

Real-time platelet P2Y12 receptor occupancy as a promising pharmacodynamics biomarker for bridging the gap between PK/PD of clopidogrel therapy

Acta Pharmaceutica Sinica B
Clopidogrel effectively inhibits platelet aggregation in response to ADP by irreversibly binding to the platelet P2Y12 receptor through its active metabolite. However, the observed discrepancies between the pharmacokinetics (PK) and pharmacodynamics (PD)
Haipeng Li, Yueming Gu, Yumeng Zhao, Aiyun Xu, Dong Sun, Jingkai Gu   +5 more
doaj   +1 more source

Antiplatelet Therapy Changes for Patients With Myocardial Infarction With Recurrent Ischemic Events: Insights Into Contemporary Practice From the TRANSLATE‐ACS (Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome) Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
BackgroundGuidelines recommend P2Y12 inhibitor therapy for 1 year after myocardial infarction (MI), yet little guidance is provided on antiplatelet management for patients with recurrent ischemic events during that year.
Alexander C. Fanaroff, Lisa A. Kaltenbach, Eric D. Peterson, Mohammed W. Akhter, Mark B. Effron, Timothy D. Henry, Tracy Y. Wang   +6 more
doaj   +1 more source

Pre‐operative anaemia, red blood cell transfusion and mortality after cardiac surgery: a Netherlands Heart Registration mediation analysis

Anaesthesia, Volume 81, Issue 5, Page 646-654, May 2026.
Summary Introduction Pre‐operative anaemia is an established risk factor for mortality after cardiac surgery. The extent to which this risk is mediated by complications related to red blood cell transfusion remains uncertain, particularly across different age groups.
Elisabeth M. Groenewegen, Peter G. Noordzij, Eline Vlot, Saskia Houterman, Toni Klok, Alexander J. Spanjersberg, Maarten Ter Horst, Joost M. A. A. Van Der Maaten, Susanne Eberl, Remco R. Berendsen, R. Arthur Bouwman, Bastiaan M. Gerritse, Thierry V. Scohy, Johannes S. E. Haenen, Jan Hofland, Marieke F. Kingma, Jan Van Klarenbosch, Sander Bramer, Marcel P. J. De Korte, Nicobert E. Wietsma, Olaf L. Cremer, Lizbeth Burgos Ochoa, Thijs C. D. Rettig, on behalf of the NHR Cardiothoracic Surgery Registration Committee of the Netherlands Heart Registration   +23 more
wiley   +1 more source

Multiscale Approximations to Understand the Complex Role of Microglia in Alzheimer's Disease

European Journal of Neuroscience, Volume 63, Issue 9, May 2026.
Microglia are dynamic, context‐dependent regulators of Alzheimer's disease, modulating amyloid, tau, and neurodegeneration across disease stages. Integrating multiscale and human‐focused approaches is essential to translate microglial biology into therapeutic strategies. ABSTRACT Microglia, the resident innate immune cells of the central nervous system,
Patricia Martínez‐Tazo, Marina Mejias‐Ortega, Verónica López‐López, Aysha M. Bhojwani‐Cabrera, Emma Saxton, Santiago Canals, Giles Hardingham, Antonia Gutierrez, Jose P. Lopez‐Atalaya, Silvia De Santis   +9 more
wiley   +1 more source

Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2).

PLoS ONE, 2016
Early stent thrombosis (EST) (≤ 30 days after stent implantation) is a relatively rare but deleterious complication of percutaneous coronary intervention (PCI). Administration of newer P2Y12 inhibitors (prasugrel and ticagrelor) combined with aspirin has
Elad Asher, Arsalan Abu-Much, Ilan Goldenberg, Amit Segev, Avi Sabbag, Israel Mazin, Meital Shlezinger, Shaul Atar, Doron Zahger, Arthur Polak, Roy Beigel, Shlomi Matetzky, Platelets and Thrombosis in Sheba-PLATIS Study Group   +12 more
doaj   +1 more source

Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers. [PDF]

, 2019
BACKGROUND: Ticagrelor is an oral P2Y12 inhibitor that is used with aspirin to reduce the risk of ischemic events among patients with acute coronary syndromes or previous myocardial infarction.
Arnold, Susan E., Bhatt, Deepak L., Jennings, Lisa K., Lee, John S., Mays, Michael C., Pollack, Charles V., Umstead, Bret R., Weitz, Jeffrey I., Xu, Sherry   +8 more
core   +1 more source

Unveiling the Molecular Mechanism of Intestinal Metabolite para‐Cresol in Modulating Neuroinflammation and Synaptic Dysfunction: Implications for Autism Spectrum Disorder

Journal of Neurochemistry, Volume 170, Issue 5, -Not available-.
Here we investigated the effect of p‐Cresol on different brain‐cell types to speculate on their specific contribution to autism spectrum disorder (ASD) synaptic dysfunctions. Our in vitro data show that p‐Cresol impairs dendritic arborization and length, disrupts the excitatory/inhibitory balance, and induces glial activation and inflammatory responses.
Wenjie Liao, Kristy Antonioni, Federica Silvestri, Monica Piemontese, Martina Bodria, Eleonora Daini, Antonio M. Persico, Michele Zoli, Andreas M. Grabrucker, Antonietta Vilella   +9 more
wiley   +1 more source

Association of perioperative P2Y12 inhibitor administration with outcomes for tandem occlusion: RESCUE AT-LVO sub-study

Frontiers in Neurology
BackgroundWe aimed to clarify the association between intraoperative P2Y12 inhibitor administration during EVT and clinical outcomes in patients with anterior circulation TO stroke.MethodsAmong consecutive patients with acute ischemic stroke (AIS ...
Takeshi Yoshimoto, Takeshi Yoshimoto, Hiroshi Yamagami, Hiroshi Yamagami, Hiroshi Yamagami, Nobuyuki Sakai, Kazutaka Uchida, Manabu Shirakawa, Mikiya Beppu, Kazunori Toyoda, Yuji Matsumaru, Yuji Matsumaru, Yasushi Matsumoto, Kenichi Todo, Mikito Hayakawa, Mikito Hayakawa, Seigo Shindo, Masafumi Morimoto, Masataka Takeuchi, Hirotoshi Imamura, Hiroyuki Ikeda, Kanta Tanaka, Kanta Tanaka, Hideyuki Ishihara, Hiroto Kakita, Takanori Sano, Takanori Sano, Hayato Araki, Tatsufumi Nomura, Fumihiro Sakakibara, Shinichi Yoshimura, for RESCUE AT-LVO Investigators   +31 more
doaj   +1 more source

Evaluation of evolocumab on saphenous vein graft patency following coronary artery bypass graft surgery in people living with and without diabetes in the NEWTON‐CABG CardioLink‐5 trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 5, Page 4376-4381, May 2026.
Hwee Teoh, Subodh Verma, G. B. John Mancini, Adrian Quan, Michael Szarek, Randi Elituv, Meena Verma, Elizabeth Misner, Aishwarya Krishnaraj, Peter Jüni, Michael J. Koren, Stephen J. Nicholls, Deepak L. Bhatt, C. David Mazer, Lawrence A. Leiter   +14 more
wiley   +1 more source

Response variability to P2Y12 receptor inhibitors: expectations and reality.

JACC. Cardiovascular interventions, 2013
P2Y12 inhibitors are widely used in patients with acute coronary syndromes and in the secondary prevention of thrombotic events in vascular diseases. Within the past few years, several pharmacological, genetic, and clinical limitations of the second-generation thienopyridine clopidogrel have raised major concerns. High on-treatment platelet reactivity,
Siller-Matula, Jolanta M, Trenk, Dietmar, Schrör, Karsten, Gawaz, Meinrad, Kristensen, Steen D, Storey, Robert F, Huber, Kurt   +6 more
openaire   +2 more sources